The role of phosphodiesterase inhibitors in impotence

Bibliography

• BENET AE, MELMAN A: The epidemiology of erectile dys-function. Uro1 Din. N. Am. (1995) 22:699–709.
   PubMed Web of Science ®Google Scholar
• REID K, SURRIDGE DH, MORALES A, FENEMORE J: Double blind trial of yohimbine in the treatment of psycho-genic impotence. Lancet (1987) 2:421–423.
   PubMed Web of Science ®Google Scholar
• SUSSET JG, TESSIER CD, WINCZE J et al.: Effect of Yo-himbine hydrochloride on erectile impotence: a dou-ble blind study. J. Urol. (1989) 141:1360–1363.
   PubMed Web of Science ®Google Scholar
• MORALES A, CONDRA M, OWEN JA et a 1: Is Yohimbine ef-fective in the treatment of organic impotence? Results of a controlled trial. J. Urol. (1987) 137:1168–1172.
   PubMed Web of Science ®Google Scholar
• STIEF CG, SCHULTHEISS D, HARTMANN U, JONAS U: Oral phentolamine as a treatment for erectile dysfunction. J. Int. Imp. Res. 8: D105.
   Google Scholar
• HEATON JPW, ADAMS MA, MORALES A et al.: Apomor-phine SL is effective in the treatment of non-organic erectile dysfunction: results of a multicentre trial. Int. Imp. Res. (1996) 8:A64.
   Google Scholar
• ABOSEIF SR, LUE TF: Haemodynamics of penile erec-tion. Uro1 Din. N. Am. (1988) 15:1–7.
   PubMed Web of Science ®Google Scholar
• •An explanation of the vascular events which produce an erection.
   Google Scholar
• GUILIANO FA, RAMPIN 0, BENOIT G, JARDIN A: Neuralcontrol of penile erection. Uro1 Din. N. Am. (1995) 22:747–766.
   Google Scholar
• Burnett AL: Role of nitric oxide in the physiology of erec-tion. Biol. Reprod. (1995) 52: 485–489.
   PubMed Web of Science ®Google Scholar
• CHRIST GJ, LERNER SE, KIM DC, MELMAN A: Endothelin-1 as a putative modulator of erectile function: I. Charac-teristics of contraction of isolated corporal tissue strips. J. Uro1 (1995) 153:1998–2003.
   Google Scholar
• DING YQ, TAKADA M, KANEKO T, MIZUNO N: Colocalisa-tion of vasoactive intestinal polypeptide and nitric ox-ide in penis-innervating neurones in the major pelvic ganglia of the rat. Neurosci. Res. (1995) 22:129–131.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, WAGNER G: Physiology of penile erec-tion. Physio1 Rev. (1995) 75:191–236.
   PubMed Web of Science ®Google Scholar
• •A full account of the physiology and pharmacology of penile erection.
   Google Scholar
• PICKARD RS, POWELL PH, ZAR MA: Nitric oxide and cy- clic GMP formation upon electrical field stimulation in isolated human corpus cavernosum. Br. J. Pharm. (1995) 75:516–522.
   Web of Science ®Google Scholar
• •Account of the role of cGMP in penile erection.
   Google Scholar
• CHRIST GJ, RICHARDS S, WINKLER A: Integrative erectile biology: the role of signal transduction and cell to cell communication in co-ordinating coporal smooth mus-cle tone and penile erection. Int. J. Imp. Res. (1997) 9:69–84.
   PubMed Web of Science ®Google Scholar
• •An account of the relaxant and contractile control of penile smooth muscle tone.
   Google Scholar
• BEAVO JA: Cyclic nucleotide phosphodiesterases: func- tional implications of multiple isoforms. PhysioL Rev. (1995) 75:725–748.
   PubMed Web of Science ®Google Scholar
• ••A full account of phosphodiesterase biology.
   Google Scholar
• MANGANIELLO VC, MURATA T, TAIRA M, BELFRAGE P, BE- GERMAN E: Diversity in cyclic nucleotide phosphodies-terase isoenzyme families. Arch. Biochem. Biophys. (1995) 322:1–13.
   PubMed Web of Science ®Google Scholar
• BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodies-terase inhibitor for the treatment of penile erectile dys-function. Intl. Imp. Res. (1996) 8:47–52.
   PubMedGoogle Scholar
• ••In vitro and clinical data from a trial of sildenafil in men witherectile dysfunction.
   Google Scholar
• TAHER A, MEYER M, STIEF CG, JONAS U, FORSSMANN WG: Cyclic nucleotide phosphodiesterase in human cavern-ous smooth muscle. World]. Uro1 (1997) 15:32–35.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REIFSNYDER DH: Primary sequence of cyclic nucleotide phosphodiesterase enzymes and the design of selective inhibitors. Trends Pharmaco1 Sc.] (1990) 11:150–155.
   PubMed Web of Science ®Google Scholar
• GILLESPIE PG, BEAVO JA: Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. MoL Pharmaco1 (1989) 36:773–781.
   PubMed Web of Science ®Google Scholar
• GREENWOOD B, TYLER K, WANG R, HELLSTROM WJG, DOHERTY PC: Stimulatory effects of zaprinast, a type 5 PDE inhibitor, on erection in the male cat. Proc. Euro-pean Soc. Imp. Res. (1997). Abstract 8.
   Google Scholar
• BALLARD SA, GINGELL CJ, PRICE ME et al.: Sildenafil, an inhibitor of phosphodiesterase type 5, enhances nitric oxide mediated relaxation of human corpus caverno-sum. Int. J. Imp. Res. (1996) 8:A17.
   PubMedGoogle Scholar
• JEREMY JY, BALLARD SA, NAYLOR AM et al.: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol. (1997) 79:958–963.
   PubMedGoogle Scholar
• BALLARD SA, TURNER LA, NAYLOR AM: Sildenafil, a po-tent selective inhibitor of type 5 phosphodiesterase en-hances nitric oxide dependent relaxation of rabbit corpus cavernosum. Br. Pharmacol. (1996) 118:153P.
   Web of Science ®Google Scholar
• BALLARD SA, BURSLEM FMF, GINGELL JC et al.: In vitro profile of UK-92,480, an inhibitor of cyclic GMP-specficic phosphodiesterase 5 for the treatment of male erectile dysfunction.' Urol. (1996) 155 (Suppl):Ab-stract 1462.
   Google Scholar
• CARTER AJ, BALLARD SA, NAYLOR AM: The effect of silde-nafil (Viagrain on erectile function in the anaesthe-tised dog. .1 Uro1 (1997) 157 (Suppl):Abstract 1398.
   Google Scholar
• CARTER AJ, BALLARD SA, NAYLOR AM: Effects of silde-nafil on intracavernosal pressure rises induced by in-jection of sodium nitroprusside into the corpus cavernosum in the anaesthetised dog. Proc. European Soc. Imp. Res. (1997). Abstract 10.
   Google Scholar
• BOOLELL M, GEPI-ATEE S, GINGELL JC, ALLEN MJ: Silde-nafil, a novel effective oral therapy for male erectile dysfunction. Br.]. Uro1 (1996) 8:57–261.
   Google Scholar
• ••Clinical data from a pilot study of sildenafil in men with erec-tile dysfunction.
   Google Scholar
• BURRIS AS, BANKS SM, SHERINS RJ: Quantitative assess- ment of nocturnal penile tumescence and rigidity in normal men using a home monitor. J. AndroL (1989) 10:492–497.
   PubMed Web of Science ®Google Scholar
• GINGELL JC, JARDIN A, OLSSON AM et al.: UK-92,480, a new oral treatment for erectile dysfunction: a double blind placebo-controlled, once daily dose response study. J. Urol. (1996)155 (Suppl):495A.
   Google Scholar
• Eardley I, Morgan RJ, Dinsmore WW et al.: UK-92,480, a new oral therapy for erectile dysfunction. A double blind placebo controlled trial with treatment taken as required. J. Urol. (1996) 155 (Supp0 :495A.
   Google Scholar
• VIRAG R, HODGES M, HOLLINGSHEAD M, KIRKPATRICK J, OSTERLOH I: Sildenafil (ViagraTm) a new oral treatment for erectile dysfunction: an 8 week double blind, pla-cebo controlled parallel group study. J. Int. Imp. Res. (1996) 8:A70.
   Google Scholar
• LUE TF AND THE SILDENAFIL STUDY GROUP: A study of sildenafil (ViagraTm) a new oral agent for the treatment of male erectile dysfunction. J. Urol. (1997) 157(Suppl):701.
   Google Scholar
• BOOLELL M, PEARSON J, GINGELL JC etaL: Sildenafil (Via-graTM) is an efficacious oral therapy in diabetic patients with erectile dysfunction. J. Int. Imp. Res. (1996) 8:P14.
   Google Scholar
• DERRY F, GARDNER BP, GLASS C et al.: Sildenafil: a dou-ble blind placebo controlled single dose, two way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury. J. UroL (1997) 157 (Suppl.):Abstract 702.
   Google Scholar
• BUVAT J, GINGELL CJ, JARDIN A et al.: Sildenafil (Via-grain, an oral treatment for erectile dysfunction: a 1 year open label extension study. Proc. European Soc. Imp. Res. (1997) Abstract 81.
   Google Scholar
• STEERS WD AND THE SILDENAFIL STUDY GROUP: Long term efficacy and safety of sildenafil (Viagrain: a 6 month randomised, double blind, placebo controlled study in men with erectile dysfunction. Proc. European Soc. Imp. Res. (1997). Abstract 80.
   Google Scholar
• EARDLEY I, BROOK J, YATES PK, WULFF MB, BOOLELL M: Sildenafil (Viagrain, a novel oral treatment with rapid onset of action for penile erectile dysfunction. Br. J. Urol. (1997) 79 (Suppl. 4):66.
   Google Scholar
• STIEF CG, UCKERT S, TRUSS MC et al.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in human cor-pus cavernous smooth muscle: characterisation and functional effects of PDE-inhibitors in vitro and in vivo. J. Int. Imp. Res (1995) 7 (Suppl. 1):6–7.
   Google Scholar